Oral<unk>  is used to prevent stroke and systemic embolization and is considered a mainstay of atrial fibrillation management.<unk>  is recommended for atrial fibrillation (AF) patients who are at high risk for stroke based on CHADS2-VASc score who do not have an unacceptable risk of bleeding (HAS-BLED score). Treatment with<unk>  can be done with warfarin, or one of the novel oral anticoagulants (NOACs). Four novel oral anticoagulants (NOACs) have been approved for use in nonvalvular atrial fibrillation (AF) as alternatives to warfarin. Anti-platelet therapy is not recommended for stroke reduction in atrial fibrillation (AF).
Atrial fibrillation anticoagulation
Ventricular fibrillation medical therapy
Atrial fibrillation cardiac surgery
Atrial fibrillation surgical ablation
ST elevation myocardial infarction glucose control
Atrial fibrillation cardiac MRI
Atrial fibrillation urgent treatment
Ventricular tachycardia medical therapy